InflaRx N.V. IFRX
InflaRx N.V. (Nasdaq: IFRX) is an immunology/inflammation drug developer. Its lead program, izicopan (oral C5aR inhibitor), is in Phase 2 for ANCA-associated vasculitis (AAV) and other complement-mediated renal disease; HS and CSU Phase 2a completed. Its next catalyst on record is vilobelimab (GOHIBIC): US EUA termination becomes effective (July 1, 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: vilobelimab (GOHIBIC) — US EUA termination becomes effective (July 1, 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vilobelimab (GOHIBIC; US EUA, EU authorization under exceptional circumstances) | SARS-CoV-2-induced ARDS / critically ill COVID-19 | antibody | Phase 3 |
| vilobelimab (anti-C5a mAb) ARDS platform study (BARDA-funded) | acute respiratory distress syndrome | antibody | Phase 2 |
| izicopan Phase 2a (completed) | hidradenitis suppurativa; chronic spontaneous urticaria | small molecule | Phase 2 |
| izicopan AAV Phase 2 (planned) | ANCA-associated vasculitis | small molecule | Phase 2 |
| vilobelimab / anti-C5a for AAV (Phase 2 IXCHANGE/IXPLORE completed) | ANCA-associated vasculitis | antibody | Phase 2 |
| IFX002 (next-generation anti-C5a antibody) | chronic inflammatory diseases | antibody | Pre-clinical |
Recent results and decisions
- Oct 22, 2026positive Izicopan demonstrated significant renal protection in pre-clinical hamster models of kidney injury.
In both settings, oral izicopan significantly attenuated renal injury compared to vehicle-treated controls.
Filing - Dec 30, 2025missed Phase 3 PG trial (54 patients, terminated for futility) missed its primary endpoint of complete target ulcer closure, 20.8% vs 16.7% (p=NS), though post-hoc ulcer-volume analyses favored vilobelimab.
The primary clinical endpoint of complete target ulcer closure on two consecutive visits showed a difference in favor of vilobelimab over placebo of 20.8% versus 16.7% (p=NS (not significant)).
Filing - Nov 10, 2025positive Phase 2a topline in HS (n=29 evaluable, 60/90/120 mg bid for 4 weeks) showed rapid reductions in abscesses/nodules and draining tunnels, HiSCR responses that deepened after treatment, and no safety signals of concern.
In HS, over 4 weeks of therapy, InflaRx observed rapid and clinically meaningful reductions in abscesses and nodules (ANs) and draining tunnels (dTs), robust HiSCR responses that continued to deepen four weeks after the treatment period.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.